Clinical trials: Aromatase Inhibitor
Breast Cancer
Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy
The objective of the study is to monitor the changes of blood coagulation parameters in postmenopausal patients who are treated with adjuvant Hormonal Therapy for a total of 5 years.
- Trial name
- COPA (NCT00814034)
- Where
- 2 sites in Greece
- Volunteers
- 306 people
- Sponsor
- Hellenic Breast Surgeons Society
Infertility
Short-Term Androgen Priming Before COS Using Aromatase Inhibitor and hCG During Early-Follicular-Phase GnRH Antagonist Administration - a Randomized Controlled Trial
We want to investigate if early follicular phase downregulation and androgen priming, by use of GnRH antagonist, aromatase inhibitor and hCG before COH in a short protocol, shows signs of improvement compared to standard short…
- Trial name
- NCT00286364
- Testing
- Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH
- Where
- Denmark
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
IVF
RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2
The goal of the randomised controlled study (RCT) is to identify novel strategies that can improve the luteal phase endocrinology after ovarian stimulation, with the aim of using less or no luteal support in IVF while making the…
- Trial name
- RIOTC (NCT04524026)
- Testing
- Letrozole 5 mg
- Where
- 2 sites in Denmark
- Volunteers
- 25 people
- Sponsor
- Nicholas Macklon
Breast Cancer, Genitourinary Syndrome of Menopause
Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy
Background: Vulvovaginal health, directly linked to sexual health, is a key factor for female pleasure. BCS receiving AI are likely to present severe GSM and sexual complaints.
- Trial name
- LIGHT (NCT04619485)
- Testing
- CO2 LASER
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Hospital Clinic of Barcelona
Breast Cancer
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
RATIONALE: Measuring how text-message affects treatment compliance in women with breast cancer may help doctors plan the best treatment.
- Trial name
- NCT01515800
- Testing
- Text message reminder
- Where
- 204 sites in United States
- Volunteers
- 724 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Cancer
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
In this Italian, multicenter, randomized, double-blind, placebo controlled, phase III study the efficacy of exemestane will be evaluated in addition to the standard front line treatment in patients with hormone-receptor-positive…
- Trial name
- EXPERT (NCT04460807)
- Testing
- Exemestane
- Where
- 47 sites in Italy
- Volunteers
- 23 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
HR+/HER2- Early Breast Cancer
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant culmerciclib in combination with aromatase inhibitors in patients with highly proliferative ER-positive/HER2-negative breast…
- Trial name
- TAYLOR-002 (NCT07616453)
- Testing
- Culmerciclib, Aromatase Inhibitors
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HR+ / HER2- Advanced Breast Cancer
Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer
This study is a prospective, single-arm, multicenter phase II clinical trial. The study plans to enroll 40 patients with HR+/HER2- advanced breast cancer to explore the efficacy and safety of patients receiving olmesartan…
- Trial name
- NCT07810088
- Testing
- Treatment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Inguinal Hernia Unilateral, Inguinal Hernia Bilateral
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias.
- Conditions
- Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
- Trial name
- RIGHT (NCT07604272)
- Testing
- Fulvestrant, Anastrozole (ARIMIDEX™)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Breast Cancer
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
This study will investigate the relationship between the endocrine therapy and the survival of patients with hormone receptor positive intraductal carcinoma of the breast, and the optimal duration of medication.
- Trial name
- NCT04666805
- Testing
- Tamoxifen, Toremifene, Anastrozole
- Where
- China
- Volunteers
- 1,354 people
- Sponsor
- First Hospital of China Medical University
Reproductive Behavior
Endometrial Preparation in Frozen Embryo Transfer Cycles
Comparison of protocols for frozen embryo transfer (ET): One protocol using Estrogen supplements and the second protocol using Letrozole
- Trial name
- NCT03540979
- Testing
- endometrial preparation for frozen blastocyst transfer, Letrozole, Ovidrel
- Volunteers
- 100 people
- Sponsor
- Meir Medical Center
Ectopic Pregnancy
Evaluation of Different Doses of Letrozole in Ectopic Pregnancy
The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.
- Trial name
- letrezole (NCT05198141)
- Testing
- Letrozole tablets, laparoscopic salpingectomy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Zagazig University
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors.
- Conditions
- Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
- Trial name
- NCT06123286
- Testing
- Tart Cherry, Omega 3 FA (Fish Oil)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Philip Chang
Breast Cancer
Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have metastatic breast…
- Trial name
- NCT00066339
- Testing
- gefitinib
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy
Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment.
- Trial name
- NCT01016665
- Testing
- Anastrozole
- Where
- Brazil
- Volunteers
- 71 people
- Sponsor
- Federal University of São Paulo
Early-stage Breast Cancer
Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors
This is a national clinical trial (Spain), conducted in approximately 5 sites, where patients who agree to participate will be included in one of two exercise program groups: the experimental group (a combined resistance and…
- Trial name
- EX-AI (NCT07215364)
- Testing
- Training program
- Where
- 5 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
The purpose of this study to gather information about changes in the bones after stopping treatment with aromatase inhibitor/AI and denosumab.
- Trial name
- NCT05590949
- Testing
- Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Physical Activity
Exercise Training in Postmenopausal Patients With Breast Cancer
This randomized trial aims to assess if a well defined subgroup of breast cancer patients benefit from a controlled physical activity program.
- Trial name
- NCT01384838
- Testing
- Counseling, physical activity
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Menstruation Disorders
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent breast cancer. They act by blocking the action of the enzyme, aromatase, that is necessary for the production of estradiol.
- Trial name
- NCT00467493
- Testing
- Anastrozole
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Meditrina Pharmaceuticals
Breast Neoplasms
Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients
The purpose of this study is to examine the immunological response rate to administration of the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated with aromatase inhibitors or Faslodex® and…
- Trial name
- NCT00046371
- Testing
- THERATOPE® vaccine
- Where
- 17 sites in United States
- Sponsor
- Oncothyreon Canada Inc.